Prometheus Biosciences (RXDX) IPO Opens 31% Higher

Today's IPO for Prometheus Biosciences Inc. (NASDAQ: RXDX) opened for trading at $24.95 after pricing 10,000,000 shares of common stock at a public offering price of $19.00 per share.

SVB Leerink, Credit Suisse, Stifel and Guggenheim Securities are acting as joint bookrunning managers for the offering.

Prometheus Biosciences, Inc. is a biotechnology company pioneering a precision medicine approach for the discovery, development, and commercialization of novel therapeutic and companion diagnostic products for the treatment and diagnosis of IBD. The company's precision medicine platform, Prometheus360, combines proprietary bioinformatics discovery methods with one of the world's largest gastrointestinal bioinformatics databases to identify novel therapeutic targets and develop therapeutic candidates to engage those targets.

You May Also Be Interested In

• Parabilis Medicines closes $770.5 million IPO and concurrent private placement
• SpaceX prices IPO at $135 per share for June 12 Nasdaq debut
• SpaceX prices historic IPO at $135/share in largest ever new listing